Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non–muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy-Reference-Cited by-同舟云学术

Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non–muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy

Published:2022-06 Issue:6 Volume:81 Page:606-614
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Mayr Roman,Eckstein Markus,Wirtz Ralph M.,Santiago-Walker Ademi,Baig Mahadi,Sundaram Ramesh,Carcione Jenna Cody,Stoehr Robert,Hartmann Arndt,Bolenz Christian,Burger Maximilian,Otto Wolfgang,Erben Philipp,Breyer Johannes

Publisher

Elsevier BV

Subject

Urology

Reference33 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016;Babjuk;Eur Urol,2017

3. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival;Shahin;J Urol,2003

4. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update;Babjuk;Eur Urol,2019

5. Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-Feasibility study;Catto;J Clin Oncol,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer;Expert Opinion on Pharmacotherapy;2024-07-02

2. Cancer-associated fibroblasts (CAFs) based model reveals potential for predicting bladder cancer patients’ prognoses and immunotherapy responses;Journal of Cancer Metastasis and Treatment;2024-02-01

3. Associations of TACSTD2/TROP2 and NECTIN‐4/NECTIN‐4 with molecular subtypes, PD‐L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts;Histopathology;2024-01-09

4. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer;Annals of Oncology;2024-01

5. Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy;npj Precision Oncology;2023-07-21